These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25536560)

  • 1. Gene polymorphisms of p53-mediated apoptosis in chronic lymphocytic leukemia patients: features of distribution depending on radiation factor in anamnesis.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV
    Probl Radiac Med Radiobiol; 2014 Sep; 19():223-30. PubMed ID: 25536560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distribution of TP53 gene polymorphisms in chronic lymphocytic leukemia patients, sufferers of Chornobyl nuclear power plant accident.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV
    Exp Oncol; 2016 Dec; 38(4):252-256. PubMed ID: 28230820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of rs2124594 genotypes in chronic lymphocytic leukemia patients depending on radiation anamnesis.
    Bilous NI; Abramenko IV; Chumak AA; Diagil IS; Martina ZV
    Probl Radiac Med Radiobiol; 2017 Dec; 22():323-331. PubMed ID: 29286517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population.
    Mohammed Basabaeen AA; Abdelgader EA; Babekir EA; Abdelrahim SO; Eltayeb NH; Altayeb OA; Fadul EA; Sabo A; Ibrahim IK
    Asian Pac J Cancer Prev; 2019 May; 20(5):1579-1585. PubMed ID: 31128065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of
    Lotfi Garavand A; Mohammadi M; Mohammadzadeh S
    Rep Biochem Mol Biol; 2020 Apr; 9(1):26-32. PubMed ID: 32821748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA repair polymorphisms in B-cell chronic lymphocytic leukemia in sufferers of Chernobyl Nuclear Power Plant accident.
    Abramenko I; Bilous N; Chumak A; Kostin A; Martina Z; Dyagil I
    J Radiat Res; 2012; 53(3):497-503. PubMed ID: 22739018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran.
    Jalilian N; Maleki Y; Shakiba E; Aznab M; Rahimi Z; Salimi M; Rhimi Z
    Int J Hematol Oncol Stem Cell Res; 2021 Jul; 15(3):160-169. PubMed ID: 35082997
    [No Abstract]   [Full Text] [Related]  

  • 11. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
    Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
    Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 codon 72 single nucleotide polymorphism in chronic lymphocytic leukemia.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martіna ZV
    Exp Oncol; 2014 Dec; 36(4):258-61. PubMed ID: 25537220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
    Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
    Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
    Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
    Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic polymorphism of DNA repair gene XRCC1 in patients with thyroid cancer who were exposed to ionizing radiation as a result of the Chornobyl accident.
    Shkarupa VM; Henyk-Berezovska SO; Neumerzhytska LV; Klymenko SV
    Probl Radiac Med Radiobiol; 2014 Sep; 19():377-88. PubMed ID: 25536575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.
    Fontecha MB; Anadón MDR; Mercado Guzmán V; Stanganelli C; Galvano C; Tosin F; Bordone J; Bezares R; Rodríguez C; Heller V; Slavutsky I; Fundia AF
    Ann Hematol; 2024 May; ():. PubMed ID: 38743086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.